PRT543

PRT543

PRT543
Identifiers
  • (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(R)-(4-chlorophenyl)-hydroxymethyl]oxolane-3,4-diol
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC17H17ClN4O4
Molar mass376.80 g·mol−1
3D model (JSmol)
  • C1=CC(=CC=C1[C@H]([C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC4=C(N=CN=C43)N)O)O)O)Cl
  • InChI=1S/C17H17ClN4O4/c18-9-3-1-8(2-4-9)11(23)14-12(24)13(25)17(26-14)22-6-5-10-15(19)20-7-21-16(10)22/h1-7,11-14,17,23-25H,(H2,19,20,21)/t11-,12+,13-,14-,17-/m1/s1
  • Key:ITEKIFMGFZAFPM-QFRSUPTLSA-N

PRT543 is an experimental anticancer drug which acts as an inhibitor of the enzyme protein arginine methyltransferase 5. This protein is involved in repairs to DNA following damage, so inhibiting it makes cancer cells more susceptible to other chemotherapy drugs. PRT543 is in early stage clinical trials against adenoid cystic carcinoma.[1][2][3][4][5]

References

  1. ^ Feustel K, Falchook GS (August 2022). "Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review". Journal of Immunotherapy and Precision Oncology. 5 (3): 58–67. doi:10.36401/JIPO-22-1. PMC 9390703. PMID 36034581.
  2. ^ Carter J, Hulse M, Sivakumar M, Burtell J, Thodima V, Wang M, et al. (November 2023). "PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies". Cancer Research Communications. 3 (11): 2233–2243. doi:10.1158/2767-9764.CRC-23-0070. PMC 10627093. PMID 37861290.
  3. ^ Ferrarotto R, Swiecicki PL, Zandberg DP, Baiocchi RA, Wesolowski R, Rodriguez CP, et al. (February 2024). "PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study". Oral Oncology. 149 106634. doi:10.1016/j.oraloncology.2023.106634. PMID 38118249.
  4. ^ Mishra V, Singh A, Korzinkin M, Cheng X, Wing C, Sarkisova V, et al. (January 2025). "PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands". Journal of Experimental & Clinical Cancer Research. 44 (1) 11. doi:10.1186/s13046-024-03270-x. PMC 11724466. PMID 39794830.
  5. ^ Bewersdorf JP, Mi X, Lu B, Kuykendall A, Sallman D, Patel M, et al. (January 2025). "Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies". Leukemia. 39 (3): 765–769. doi:10.1038/s41375-025-02515-8. PMC 11879867. PMID 39856223.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.